European healthcare stocks ended a run of gains in October, raising concerns for drugmakers like Novo Nordisk (NVO.US)
Monday, Sep 30, 2024 6:50 am ET
1min read European healthcare stocks' longest winning streak since March 2010 is set to end as investors fret over Novo Nordisk's (NVO.US) upcoming third-quarter results and updates on experimental drugs from AstraZeneca (AZN.US) and Roche (RHHBY.US), data show. The Stoxx 600 healthcare index has fallen 6.1% this month, ending a 10-month winning streak, with Novo Nordisk, AstraZeneca and Roche accounting for about 90% of the decline since the start of the month.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.